Metabolic syndrome in people with epilepsy

Little is known about the association of metabolic syndrome (MetS) and quality of life (QoL) in people with epilepsy (PWE). We evaluate the trends of MetS in PWE across various age groups. We also evaluate the association of MetS and QoL in PWE. Clinical and seizure data were collected in 173 people with controlled epilepsy. Physical fitness was assessed by using the six-minute walk test and one-minute step test. Self-reported SF-12 questionnaire, was used to derive physical (PCS) and mental (MCS) component scores. The average age of the study population was 25.85 ± 9.62 years, and MetS was observed in 91 (52.6%). Obesity was seen in 153 (88.4%). Average distance walked in the six-minute walk test was 385.55 ± 71.52 m. Mean PCS and MCS were 45.95 ± 7.92 and 45.72 ± 10.40, respectively. More number of women had MetS (47.6% vs. 62.6%; p = 0.049) and women in the study population had lower high-density lipoprotein (HDL)-C (44.34 ± 11.60 vs. 38.65 ± 10.13 mm Hg; p 40 years. Metabolic syndrome is seen in more than half of PWE, and this increased prevalence is not associated with the number of antiepileptic medicines. While prevalence of MetS was stable at 50.0% across all age groups, components of MetS have varying prevalence across age groups hence, suggesting their varied contribution across age groups. •In people with epilepsy (PWE), little is known about metabolic syndrome (MetS).•We also evaluated the association between MetS and quality of life in PWE.•Metabolic syndrome is seen in more than half of PWE.•Prevalence of MetS was stable across all age groups, but components of MetS vary.